Tumor cells alter lipid metabolic pathways to meet their demands for energy and membrane biosynthesis. Despite its crucial role in tumor cell growth, survival, and metastasis, the mechanisms underlying tumor cell lipid metabolic reprogramming remain poorly understood. Pre-B-cell leukemia transcription factor 3 (PBX3), a member of the PBX family, could promote tumorigenesis; however, whether it is involved in tumor lipid metabolic reprogramming remains unknown. Herein, we found that PBX3 significantly promotes tumor growth by enhancing lipid accumulation in HCC cells. By assessing the effect of PBX3 on the expression levels of lipid metabolism-related genes, we found that PBX3 could positively regulate the expression of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), a rate-limiting enzyme in the cholesterol biosynthesis pathway. Mechanistically, we revealed that PBX3 could directly bind to the −167/−151 region of HMGCR promoter, thereby increasing its transcriptional activity and, subsequently, its expression level. This leads to the increase of HCC cell cholesterol biosynthesis and, eventually, to the increase of the in vivo tumorigenic potential. Collectively, our research revealed an unprecedented regulatory mechanism of cholesterol metabolism in HCC cells through PBX3 positive regulation on HMGCR expression levels. These findings provide novel insights into tumor metabolic reprogramming and uncover a previously unknown physiological function for PBX3. Moreover, these results suggest the potential of targeting PBX3 as an anti-tumor therapeutic strategy.
Among primary central nervous system malignancies in adults, malignant glioma ranks first in incidence, with glioblastoma (GBM) standing as its most aggressive phenotype. This malignancy remains a devastating disease with limited therapeutic options, largely owing to the intricate network of dysregulated signaling pathways. SUMOylation, a post-translational modification that governs thousands of substrate proteins, is markedly hyperactivated in GBM and represents a rational but underexploited target. Here, we found that honokiol (HNK), a natural biphenolic compound extracted from the traditional Chinese medicine Magnolia species, suppressed SUMOylation in glioma cells, with a more prominent reduction in SUMO1-conjugated species than in SUMO2/3-conjugated species. Through a combination of label-free proteomic screening and functional biological assays, we pinpointed YAP1, a core Hippo pathway effector and established oncogenic driver in glioma cells, as a critical downstream target. Furthermore, our research indicated that inhibition of SUMOylation by HNK was associated with reduced levels of YAP1, resulting in glioma cell growth inhibition. Mechanistically, HNK induced YAP1 ubiquitin–proteasome degradation by disrupting SUMO1-YAP1 conjugation, leading to the subsequent blockade of YAP1 signaling. Collectively, our findings unveiled a previously unrecognized mechanism linking pharmacological deSUMOylation to YAP1 destabilization and emphasized the SUMO–YAP1 interface as a therapeutically actionable vulnerability. Overall, this work provides a strong rationale for developing HNK or its optimized derivatives as a first-in-class therapeutic strategy that addresses the network-level complexity of GBM.